Breaking News, Financial News

Merck Revenues up 22% for the Year to $59.3B

Pharmaceutical sales top $52.0 billion for the year, up 22% driven by Keytruda; LAGEVRIO (molnupiravir) sales drop 13% in the quarter.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck 4Q Revenues: $13.8 billion (+2%) 4Q Earnings: $3.0 billion (-21%) FY Revenues: $59.3 billion (+22%) FY Earnings: $14.5 billion (+18%) Comments: Pharmaceutical sales were $12.2 billion in the quarter, up 1% and $52.0 billion for the year, up 22%. Keytruda sales were $5.5 billion in the quarter, up 19% and $20.9 billion for the year, up 22%. GARDASIL sales were $1.5 billion int he quarter, down 4% and $6.9 billion for the year, up 22%. LAGEVRIO sales were $825 million in the quarter, do...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters